Candidemia / invasive candidiasis — fellow's quick read

Personal study digest for a new ID fellow. Recommendations are drawn from the IDSA 2016 candidiasis guideline (Pappas et al., CID 2016) with the current ECMM/ISHAM/ASM global guideline (Cornely et al., Lancet Infect Dis 2025) and the local Michigan and our institution CPGs for context. The “What’s changed since 2016” section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline. This 2026-07-20 refresh supersedes the 2026-06-16 digest: it adds the shift to targeted fundoscopy, the explicit oral step-down criteria, and the mandatory ID-consult recommendation, and corrects the global-guideline DOI.

In one line

Yeast in a blood culture is never a contaminant. Start an echinocandin first-line, pull the line, get an ID consult, repeat cultures to clearance, and treat 14 days from the first negative culture when there’s no metastatic focus.

◆When to suspect / diagnose

Any Candida from a blood culture is treated as real disease — never a contaminant. Routine bottles grow it; collect 2–3 sets (40–60 mL total) — yield rises with blood volume.
Risk factors: central venous catheter, TPN, prolonged broad-spectrum antibiotics, abdominal surgery / GI perforation, hematologic malignancy, transplant, neutropenia, multifocal Candida colonization, ICU stay. Newer: IL-17 inhibitors.
Speciate and run susceptibilities (EUCAST/CLSI) on every isolate — strong rec. Test azole susceptibility on all; add echinocandin testing after prior echinocandin exposure or with C. glabrata / C. parapsilosis. MALDI-TOF for rapid ID; sequence when a problematic species (e.g. C. auris) is possible.
Serum β-D-glucan is an adjunct with high negative predictive value but poor specificity — a positive BDG alone should not start therapy.

◆Workup the fellow drives

Repeat blood cultures daily (q1–2 d) to document the day of clearance — the treatment clock starts there. Persistent cultures at day 5 → re-hunt for an uncontrolled source (retained line, deep abscess, endocarditis, septic thrombus).
Dilated fundoscopy — now targeted, not universal. IDSA 2016 asked for a dilated retinal exam in all candidemia patients; the 2025 global guideline restricts it to ocular symptoms, persistent candidemia, immunosuppression, or a patient who can’t verbalize complaints. In neutropenia, defer until count recovery — chorioretinal findings are blunted. (See “What’s changed.”)
Echocardiography (TEE) for suspected endocarditis (new murmur, skin lesions), persistent candidemia, valve disease, or a cardiac implantable device — chase endocarditis and suppurative thrombophlebitis.
Right-upper-quadrant pain or persistent fever after count recovery in a heme patient → image for chronic disseminated (hepatosplenic) candidiasis.

◆Empiric & definitive therapy

Scenario	Drug / dose / route	Notes / strength
First-line (all candidemia)	Echinocandin: micafungin 100 mg IV daily · caspofungin 70 mg load → 50 mg daily · anidulafungin 200 mg load → 100 mg daily · rezafungin 400 mg wk 1 → 200 mg weekly	Strong rec, high-quality evidence (neutropenic & non-neutropenic). Class considered interchangeable; pick by PK (hepatic impairment, weight, ECMO, interactions), cost, formulary
Fluconazole (selected)	800 mg (12 mg/kg) load → 400 mg (6 mg/kg) daily, IV/PO	Acceptable alternative only if not critically ill & unlikely fluconazole-resistant; no recent azole exposure
Septic shock (empiric)	Echinocandin	Moderate rec if shock or deteriorating + candidemia risk factors. Do NOT treat ICU fever alone (EMPIRICUS)
C. glabrata	Continue echinocandin; step down only to high-dose fluconazole 800 mg or voriconazole if susceptible	Frequent azole resistance; emerging echinocandin resistance
C. krusei	Echinocandin (intrinsically fluconazole-resistant); voriconazole for oral step-down	Never fluconazole
C. auris	Echinocandin first-line; contact isolation + screening	>95% fluconazole-R, ~15% AmB-R, ~1% echinocandin-R (watch for resistance ON therapy)
Azole/echino- resistant	Liposomal amphotericin B 3–5 mg/kg IV daily	Also the option in intolerance / limited availability

The oral step-down checklist — switch after ≥5 days only if ALL six

(1) hemodynamically stable · (2) documented blood-culture clearance · (3) non-neutropenic · (4) source controlled (e.g. line out) · (5) tolerating oral therapy · (6) isolate azole-susceptible → step down to fluconazole 400 mg daily (voriconazole for C. krusei / azole-R C. glabrata). Usually feasible around day 5–7. ECMM 2025, Figure 2

◆Key decisions a fellow owns

Remove the central venous catheter as early as possible (<48–72 h) when it is the presumed source and removal is safe (strong rec) — the biggest modifiable mortality lever in non-neutropenic candidemia.
Get a formal ID / clinical-microbiology consult on every candidemia (strong rec) — guideline-concordant care tracks with better survival (ECMM Candida III).
Echinocandin, not fluconazole, for anyone critically ill or azole-exposed — reserve fluconazole for the stable, low-risk patient.
C. parapsilosis carries innately higher echinocandin MICs → if the isolate is fluconazole-susceptible and the patient is stable/responding, transition to fluconazole.
Know where echinocandins fail by tissue: poor penetration of eye, CNS, and urine — switch to fluconazole or AmB for endophthalmitis, meningitis, or urinary candidiasis.

◆Duration & stopping

Candidemia without metastatic complications: 14 days after the first documented negative blood culture (ECMM: 14 days from the first of ≥3 consecutive negatives) AND resolution of attributable symptoms — applies to neutropenic patients too, once counts recover.
Metastatic disease lengthens therapy: endophthalmitis ≥4–6 weeks; endocarditis ≥6 weeks after valve surgery (surgery within the first week; lifelong fluconazole suppression if inoperable); chronic disseminated (hepatosplenic) candidiasis for weeks–months until lesions resolve.

What’s changed since 2016

Reviewer synthesis of newer evidence — not the guideline. Each claim cited; flags where the IDSA 2016 guideline lags current practice. IDSA 2016 remains the US guideline; the 2025 ECMM/ISHAM/ASM global guideline is the current comprehensive update.

Fundoscopy is now TARGETED, not universal — the single most practice-relevant divergence for a fellow. IDSA 2016 (rec 82) asked for a dilated retinal exam in every candidemia patient; the 2025 global guideline reserves it for ocular symptoms, persistent candidemia, immunosuppression, or a patient unable to verbalize complaints — routine screening of everyone is low-yield. Global Guideline, Lancet Infect Dis 2025;25:e280–e293 (doi)
Rezafungin — first new echinocandin in a decade (once-weekly: 400 mg week 1 → 200 mg weekly). ReSTORE (phase 3) was non-inferior to caspofungin (day-14 global cure 59% vs 61%; 30-day mortality 24% vs 21%); FDA-approved 2023. The 2025 global guideline lists it as a strong first-line option alongside the daily echinocandins. Thompson GR 3rd et al., ReSTORE, Lancet 2023;401:49–59 (PMID 36442484; doi)
An explicit 6-criterion oral step-down framework is now formal — switch to an oral azole after ≥5 days only if hemodynamically stable, bloodstream cleared, non-neutropenic, source controlled, oral azole tolerated, and susceptibility confirmed. Global Guideline, Lancet Infect Dis 2025 (doi)
Formal ID / clinical-microbiology consultation for every candidemia is a strong rec — higher guideline adherence (EQUAL Candida score) was an independent predictor of lower mortality in the ECMM Candida III European cohort (632 patients; 90-day mortality 43%; initial echinocandin also tied to lower mortality). Hoenigl M et al., Candida III, Lancet Infect Dis 2023;23:751–761 (PMID 37254300; doi)
Don’t treat fever alone in the ICU. EMPIRICUS found empiric micafungin in colonized, septic ICU patients did NOT improve day-28 invasive-fungal-infection-free survival (68% vs 60.2%, HR 1.35, 95% CI 0.87–2.08) — it cut new proven IFI (3% vs 12%) but not mortality. Reserve empiric antifungals for septic shock + risk factors. Timsit JF et al., EMPIRICUS, JAMA 2016;316:1555–1564 (PMID 27706483; doi)
BDG is endorsed to STOP, not start, empiric antifungals (moderate); no biomarker or molecular test is strong enough to start pre-emptive therapy alone. Global Guideline, Lancet Infect Dis 2025 (doi)
Candida auris is the new must-know — multidrug-resistant and transmissible; screen high-risk admissions and close contacts (composite axilla/groin swabs), isolate, clean with sporicidal agents (H₂O₂ / peracetic acid / chlorine, not quaternary ammonium), de-isolate after 3 negative screens ≥24 h apart, and treat with an echinocandin first-line. The 2016 guideline predates it. Global Guideline, Lancet Infect Dis 2025 (doi)
Oral pipeline maturing — confirm status before use. Ibrexafungerp (oral glucan-synthase inhibitor; approved for VVC 2021) is in the phase-3 MARIO trial as oral step-down for invasive candidiasis — FDA clinical hold lifted and dosing resumed May 2025 (~25% enrolled). Fosmanogepix (oral/IV Gwt1 inhibitor) is in the phase-3 FAST-IC candidemia/invasive-candidiasis trial (Basilea, NCT05421858); not yet approved. Recency-sensitive — verify current approval/trial status before clinical use. MARIO NCT05178862; FAST-IC NCT05421858; manufacturer releases 2025–2026
Rapid non-culture diagnostics keep advancing — T2Candida (T2MR) and PCR panels shorten time-to-species; recent work uses T2Candida + biomarkers to gauge whether a candidemia is catheter-derived. Still adjuncts to culture, not replacements. Soriano-Martín A et al., Open Forum Infect Dis 2026 (doi)

◆Anki cards minted this run

Fundoscopy is now TARGETED (symptoms / persistent / immunosuppressed / can’t verbalize), not universal — IDSA 2016 → ECMM 2025 shift. [currency, discriminating]
Oral azole step-down after ≥5 days — the 6 prerequisites. [core actionable framework]
ECMM Candida III — guideline-adherent candidemia care → better survival; strong rec for formal ID consult. [fellow-level systems]

Held (already in deck, verified): echinocandin first-line; rezafungin once-weekly + ReSTORE; C. auris echinocandin-first; anidulafungin vs fluconazole (Reboli); echinocandin concentration-dependent PK; persistent candidemia ≥5 d → mortality (Candida III); optho consult for endophthalmitis; intravitreal antifungals; 14-day duration; EMPIRICUS; C. parapsilosis higher echinocandin MICs. Held under bar: BDG-to-stop and CVC-removal-timing (adjacent to existing cards).

Sources: IDSA 2016 candidiasis guideline — Pappas PG et al., Clin Infect Dis 2016;62(4):e1–e50 (doi:10.1093/cid/civ933); Global Guideline for the diagnosis & management of candidiasis (ECMM/ISHAM/ASM) — Cornely OA et al., Lancet Infect Dis 2025;25:e280–e293 (doi:10.1016/S1473-3099(24)00749-7); ReSTORE/rezafungin — Thompson GR 3rd et al., Lancet 2023;401:49–59 (PMID 36442484; doi:10.1016/S0140-6736(22)02324-8); EMPIRICUS — Timsit JF et al., JAMA 2016;316:1555–1564 (PMID 27706483; doi:10.1001/jama.2016.14655); ECMM Candida III guideline-adherence/survival — Hoenigl M et al., Lancet Infect Dis 2023;23:751–761 (PMID 37254300; doi:10.1016/S1473-3099(22)00872-6); anidulafungin vs fluconazole — Reboli AC et al., NEJM 2007;356:2472–2482; T2Candida/CVC origin — Soriano-Martín A et al., Open Forum Infect Dis 2026 (doi:10.1093/ofid/ofag411); Michigan Medicine Candidemia CPG 2021; our institution Candidemia (Non-Neutropenic) CPG 2020. Trial data verified via PubMed; ibrexafungerp/fosmanogepix status via ClinicalTrials.gov + manufacturer releases (recency-sensitive).